Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Investigate The Effect Of Pd-217,014 In Patients With Irritable Bowel Syndrome (IBS)

NCT00139672 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00139672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00139672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Investigate The Effect Of Pd-217,014 In Patients With Irritable Bowel Syndrome (IBS)
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2004
Completion date
February 28, 2005
Enrollment
330
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome